دورية أكاديمية
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.
| العنوان: | Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. |
|---|---|
| المؤلفون: | Wallace DJ; Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California, USA., Strand V; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California, USA., Merrill JT; Department of Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA., Popa S; Republican Clinical Hospital, Chisinau, Moldova., Spindler AJ; Centro Medico Privado de Reumatologia, Tucuman, Argentina., Eimon A; CEMIC, Buenos Aires, Argentina., Petri M; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Smolen JS; Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria., Wajdula J; Pfizer Inc, Collegeville, Pennsylvania, USA., Christensen J; Pfizer Inc, Cambridge, Massachusetts, USA., Li C; Pfizer Inc, Cambridge, Massachusetts, USA., Diehl A; Pfizer Inc, Collegeville, Pennsylvania, USA., Vincent MS; Pfizer Inc, Cambridge, Massachusetts, USA., Beebe J; Pfizer Inc, Cambridge, Massachusetts, USA., Healey P; Pfizer Inc, Groton, Connecticut, USA., Sridharan S; PPD Inc, Rockville, Maryland, USA. |
| المصدر: | Annals of the rheumatic diseases [Ann Rheum Dis] 2017 Mar; Vol. 76 (3), pp. 534-542. Date of Electronic Publication: 2016 Sep 26. |
| نوع المنشور: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial |
| اللغة: | English |
| بيانات الدورية: | Publisher: BMJ Country of Publication: England NLM ID: 0372355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic) Linking ISSN: 00034967 NLM ISO Abbreviation: Ann Rheum Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : BMJ Original Publication: London : H.K. Lewis |
| مواضيع طبية MeSH: | Antibodies, Monoclonal/*administration & dosage , Antibodies, Monoclonal/*adverse effects , Antibodies, Monoclonal, Humanized/*administration & dosage , Antibodies, Monoclonal, Humanized/*adverse effects , Interleukin-6/*antagonists & inhibitors , Lupus Erythematosus, Systemic/*drug therapy, Adult ; Diarrhea/chemically induced ; Female ; Headache/chemically induced ; Humans ; Injections, Subcutaneous ; Male ; Middle Aged ; Nausea/chemically induced ; Pulmonary Embolism/chemically induced ; Sepsis/chemically induced ; Severity of Illness Index ; Symptom Flare Up |
| مستخلص: | Objectives: This phase II trial evaluated the efficacy and safety of an interleukin (IL) 6 monoclonal antibody for systemic lupus erythematosus (SLE). Methods: Patients with active disease were randomised to placebo or PF-04236921 10 mg, 50 mg or 200 mg, subcutaneously, every 8 weeks with stable background therapy. SLE Responder Index (SRI-4; primary end point) and British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) were assessed at week 24. Post hoc analysis identified an enriched population based upon planned univariate analyses. Results: 183 patients received treatment (placebo, n=45; 10 mg, n=45; 50 mg, n=47; 200 mg, n=46). The 200 mg dose was discontinued due to safety findings and not included in the primary efficacy analysis. The SRI-4 response rates were not significant for any dose compared with placebo; however, the BICLA response rate was significant for 10 mg (p=0.026). The incidence of severe flares was significantly reduced with 10 mg (n=0) and 50 mg (n=2) combined versus placebo (n=8; p<0.01). In patients with greater baseline disease activity (enriched population), the SRI-4 (p=0.004) and BICLA (p=0.012) response rates were significantly different with 10 mg versus placebo. Four deaths (200 mg, n=3; 10 mg, n=1) occurred. The most frequently reported adverse events included headache, nausea and diarrhoea. Conclusions: PF-04236921 was not significantly different from placebo for the primary efficacy end point in patients with SLE. Evidence of an effect with 10 mg was seen in a post hoc analysis. Safety was acceptable for doses up to 50 mg as the 200 mg dose was discontinued due to safety findings. Trial Registration Number: NCT01405196; Pre-results. (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.) |
| References: | Clin Exp Rheumatol. 1995 Jan-Feb;13(1):17-22. (PMID: 7774098) Ann Rheum Dis. 2016 Feb;75(2):323-31. (PMID: 26338095) Arthritis Rheum. 2010 Feb;62(2):542-52. (PMID: 20112381) Rheumatology (Oxford). 2013 May;52(5):905-9. (PMID: 23307831) Lancet. 2011 Feb 26;377(9767):721-31. (PMID: 21296403) Expert Rev Pharmacoecon Outcomes Res. 2005 Jun;5(3):317-26. (PMID: 19807601) Nature. 2006 May 11;441(7090):235-8. (PMID: 16648838) J Clin Immunol. 2007 Sep;27(5):461-6. (PMID: 17587156) Cell Immunol. 2010;264(1):97-103. (PMID: 20553755) Annu Rev Immunol. 1983;1:175-210. (PMID: 6399976) Folia Histochem Cytobiol. 2011;49(4):646-53. (PMID: 22252759) Ann Rheum Dis. 2014 Jan;73(1):183-90. (PMID: 23313811) Arthritis Rheum. 1981 Apr;24(4):577-83. (PMID: 6971105) Ann Rheum Dis. 2015 Sep;74(9):1667-75. (PMID: 24748629) Ann Rheum Dis. 2015 Nov;74(11):2006-15. (PMID: 24951103) Ann Rheum Dis. 2016 Nov;75(11):1909-1916. (PMID: 27009916) Exp Dermatol. 1995 Feb;4(1):52-7. (PMID: 7757333) Hepatology. 1990 Nov;12(5):1179-86. (PMID: 1699862) Arthritis Rheum. 2011 Dec;63(12):3918-30. (PMID: 22127708) Arthritis Rheum. 2009 Sep 15;61(9):1168-78. (PMID: 19714604) Rheumatology (Oxford). 2013 Dec;52(12):2292-301. (PMID: 24049101) Annu Rev Immunol. 1990;8:253-78. (PMID: 2188664) J Clin Pathol. 2003 Jul;56(7):481-90. (PMID: 12835292) J Thromb Haemost. 2014 Apr;12(4):452-8. (PMID: 24472157) J Immunol. 1991 Jul 1;147(1):117-23. (PMID: 2051017) Lupus. 1998;7(3):154-8. (PMID: 9607638) Lupus. 2004;13(5):339-43. (PMID: 15230289) Ann Rheum Dis. 2016 Feb;75(2):332-40. (PMID: 26293163) Arthritis Res. 2002;4 Suppl 3:S233-42. (PMID: 12110143) Curr Opin Organ Transplant. 2011 Feb;16(1):15-20. (PMID: 21150611) Ann Rheum Dis. 2012 Aug;71(8):1343-9. (PMID: 22337213) Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18460-5. (PMID: 19015529) Nat Immunol. 2003 Jun;4(6):540-5. (PMID: 12754505) |
| فهرسة مساهمة: | Keywords: Autoimmune Diseases; Cytokines; Systemic Lupus Erythematosus; Treatment |
| سلسلة جزيئية: | ClinicalTrials.gov NCT01405196 |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal) 0 (Antibodies, Monoclonal, Humanized) 0 (Interleukin-6) 2NHW9AKY9C (PF-04236921) |
| تواريخ الأحداث: | Date Created: 20160928 Date Completed: 20170613 Latest Revision: 20191210 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC5446001 |
| DOI: | 10.1136/annrheumdis-2016-209668 |
| PMID: | 27672124 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1468-2060 |
|---|---|
| DOI: | 10.1136/annrheumdis-2016-209668 |